EXTON, PA — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced that John Maslowski, President and Chief Executive Officer, will present at the 21st Annual BIO CEO & Investor Conference today, February 11 at 9:45 am EST in New York City.
Mr. Maslowski will discuss the Company’s gene therapy candidates for rare diseases: FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating genetic skin disease with a high mortality rate, and FCX-013 for the treatment of moderate to severe localized scleroderma, a chronic, debilitating genetic skin disorder with no therapies approved by the U.S. Food and Drug Administration.
A live webcast of Fibrocell’s presentation will be available under the Investors section of the Company’s website at www.fibrocell.com/investors/events and a replay will be available for 30 days following the event.
Source: Fibrocell Science Inc., 405 Eagleview Blvd, Exton PA 19341
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.